Gossamer Bio, Inc. (GOSS)
| Previous Close | 0.7554 |
| Open | 0.7630 |
| Bid | 0.7247 x 1000 |
| Ask | 0.7362 x 500 |
| Day's Range | 0.7211 - 0.7653 |
| 52 Week Range | 0.4530 - 1.8800 |
| Volume | |
| Avg. Volume | 1,741,285 |
| Market Cap | 165.434M |
| Beta (5Y Monthly) | 1.74 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.1800 |
| Earnings Date | Aug 06, 2024 - Aug 12, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.09 |
Business WireGossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update
SAN DIEGO, May 07, 2024--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the first quarter ended March 31, 2024, and provided a business update.
- Reuters
UPDATE 1-Gossamer Bio and Chiesi Group to collaborate in therapy for lung condition
Gossamer Bio said on Monday it will collaborate with Italian drugmaker Chiesi Group to develop and commercialize its therapy seralutinib in multiple indications related to high blood pressure due to constriction of lung arteries. The therapy is currently in late-stage development for the treatment of pulmonary arterial hypertension (PAH), which affects about 40,000 people in the United States. Gossamer is to receive $160 million in development reimbursement payment and is eligible to receive up to $146 million in regulatory and $180 million in sales milestones as part of the deal.
Business WireGossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications
SAN DIEGO, Calif. & PARMA, Italy, May 06, 2024--Gossamer Bio, Inc. ("Gossamer") (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension, and Chiesi Farmaceutici S.p.A ("Chiesi Group"), an international, research-focused biopharmaceutical group, today announced that they have entered into a global collaboration and license agreement to develop and commercialize seralutinib.
